Spots Global Cancer Trial Database for Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients
Official Title: Plasmacytoid Dendritic Cells in Vaccination of Stage IV Melanoma Patients: a Phase I Study
Study ID: NCT01690377
Conditions
Interventions
Study Description
Brief Summary: Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have been observed. Several subsets of dendritic cells have been characterized in the peripheral blood. One such subset is referred to as plasmacytoid dendritic cells (PDC), another as myeloid dendritic cells (myDC). To date PDC and myDC have not been evaluated for their capability to induce anti-tumor immune responses in patients. For this reason the investigators will perform a safety and efficacy study with PDC and myDC in stage IV melanoma patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Radboud University Nijmegen Medical Centre, Nijmegen, , Netherlands
Contact Details
Name: C J A Punt, MD, PhD
Affiliation: Radboud University Medical Center
Role: PRINCIPAL_INVESTIGATOR
Name: C G Figdor, PhD
Affiliation: Radboud University Nijmegen Medical Centre / Nijmegen Centre for Molecular Life Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
